Trial Profile
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs Tozadenant (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Biotie Therapies Corp.
- 31 Mar 2022 This trial has been completed in Czech Republic (End Date: 16 Jan 2018) according to European Clinical Trials Database record.
- 13 Dec 2017 Planned End Date changed from 31 Jul 2019 to 5 Jan 2018.
- 13 Dec 2017 Planned primary completion date changed from 31 Jul 2019 to 5 Jan 2018.